Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,268.48 -38.53 (-0.73%) Dow
39,080.25 -590.79 (-1.49%) Nasdaq
16,734.25 -67.29 (-0.40%) Bitcoin USD
66,811.70 -2,601.34 (-3.75%) CMC Crypto 200
1,459.51 -43.15 (-2.87%)
AB Science S.A. (0Q77.L)
| Previous close | 2.0500 |
| Open | 2.0900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.0700 - 2.0950 |
| 52-week range | 1.5660 - 6.6800 |
| Volume | |
| Avg. volume | 5,479 |
| Market cap | 839,275 |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AB Science reports its revenues for the year 2023 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with the European Medicines Agency (EMA) and Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)First complete bone marrow response in an acute myeloid leukemia patient in its AB8939 Phase I/II clinical trialNew clinical development program for masiti
- GlobeNewswire
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A EUROPEAN PATENT FOR MASITINIB IN THE TREATMENT OF SEVERE MASTOCYTOSIS WITH PROTECTION UNTIL 2036 Paris, May 13, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib (patent EP 3359195A1). This new European patent provides intellectual property (IP) protection for masitin
- GlobeNewswire
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS THIS PUBLICATION VALIDATES THE CLINICAL TRIAL DESIGN OF MASITINIB PHASE 2/3 STUDY AB10015 AND CONFIRMATORY STUDY IN ALS Paris, May 07, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of an article in Muscle & Nerv
